Investment analysts at Evercore ISI initiated coverage on shares of AbbVie Inc. (NYSE:ABBV) in a research note issued on Wednesday, The Fly reports. The brokerage set an “outperform” rating on the stock.

A number of other research firms also recently commented on ABBV. Vetr upgraded AbbVie from a “buy” rating to a “strong-buy” rating and set a $74.38 price objective on the stock in a report on Monday, May 8th. Credit Suisse Group reiterated a “neutral” rating and issued a $74.00 price objective (up previously from $65.00) on shares of AbbVie in a report on Thursday, July 20th. BMO Capital Markets set a $63.00 price objective on AbbVie and gave the company a “hold” rating in a report on Thursday, April 27th. BidaskClub upgraded AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 10th. Finally, Leerink Swann restated a “market perform” rating on shares of AbbVie in a research note on Thursday, June 22nd. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $74.66.

AbbVie (NYSE:ABBV) traded up 0.11% during midday trading on Wednesday, hitting $70.42. The company had a trading volume of 4,751,583 shares. AbbVie has a 12 month low of $55.06 and a 12 month high of $75.04. The firm has a 50-day moving average price of $71.93 and a 200-day moving average price of $66.99. The company has a market cap of $112.26 billion, a price-to-earnings ratio of 17.32 and a beta of 1.50.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, July 28th. The company reported $1.42 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.02. AbbVie had a return on equity of 150.27% and a net margin of 24.77%. The business had revenue of $6.94 billion for the quarter, compared to the consensus estimate of $6.93 billion. During the same quarter in the prior year, the business posted $1.26 EPS. The business’s revenue for the quarter was up 7.6% on a year-over-year basis. Equities analysts anticipate that AbbVie will post $5.52 EPS for the current year.

WARNING: This article was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/08/16/abbvie-inc-abbv-receives-new-coverage-from-analysts-at-evercore-isi.html.

In other AbbVie news, insider Laura J. Schumacher sold 79,800 shares of the stock in a transaction that occurred on Wednesday, June 14th. The stock was sold at an average price of $70.00, for a total transaction of $5,586,000.00. Following the completion of the sale, the insider now directly owns 187,625 shares of the company’s stock, valued at approximately $13,133,750. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Chairman Richard A. Gonzalez sold 193,131 shares of the stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $71.00, for a total value of $13,712,301.00. Following the sale, the chairman now directly owns 469,623 shares of the company’s stock, valued at $33,343,233. The disclosure for this sale can be found here. Insiders have sold a total of 600,026 shares of company stock valued at $41,852,724 over the last ninety days. 0.23% of the stock is owned by insiders.

A number of hedge funds have recently bought and sold shares of the company. Formidable Asset Management LLC boosted its stake in AbbVie by 0.3% in the second quarter. Formidable Asset Management LLC now owns 3,926 shares of the company’s stock valued at $285,000 after buying an additional 10 shares in the last quarter. WealthTrust Axiom LLC boosted its stake in AbbVie by 0.3% in the second quarter. WealthTrust Axiom LLC now owns 4,307 shares of the company’s stock valued at $312,000 after buying an additional 15 shares in the last quarter. Abner Herrman & Brock LLC boosted its stake in AbbVie by 0.3% in the second quarter. Abner Herrman & Brock LLC now owns 6,293 shares of the company’s stock valued at $456,000 after buying an additional 18 shares in the last quarter. Bollard Group LLC boosted its stake in AbbVie by 0.5% in the second quarter. Bollard Group LLC now owns 3,764 shares of the company’s stock valued at $273,000 after buying an additional 19 shares in the last quarter. Finally, St. Louis Trust Co boosted its stake in AbbVie by 0.7% in the second quarter. St. Louis Trust Co now owns 3,411 shares of the company’s stock valued at $248,000 after buying an additional 23 shares in the last quarter. 67.69% of the stock is owned by institutional investors.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

The Fly

Analyst Recommendations for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.